A representative from EntomoPharm will be attending the following conferences in February and March 2012. Please contact us prior to the conference to book meeting. We’d be happy to meet you.
European Drug Discovery
Brussels, Belgium
February 23-24, 2012
Clinically Relevant Drug Transporters
Berlin, Germany
February 27-29, 2012
ADME & Predictive Toxicology
Munich, Germany
March 13-14, 2012
The vision of the project is to establish insects, as a novel model organism in preclinical research. EntomoPharm has previously developed two models for ADME drug screening in locusts. From this work and from preliminary insect studies it is evident that many new and commercially viable insect models can be developed. To fulfill the vision of the project EntomoPharm, Lundbeck and the University of Copenhagen has initiated collaboration where each of the parties will deliver value through their specific expertise in insect ADME modeling, CNS drug development and miniaturization of analytical techniques.
While the current in vitro (cell based) systems are too simple and do not reflect the complexity of a human blood brain barrier, the traditional animal models (in vivo) may be too expensive and time consuming to be used as screening models. The new insect models shall fill the gap between the traditional in vitro and in vivo blood brain barrier models and minimize the time and cost for developing a new drug whilst enabling a reduction in the use of rodents and larger animals in drug discovery.
The project has received funding from the Danish National Advanced Technology Foundation and are planned to take place over the coming 3 years. The project will be carried out by EntompPharm, Lundbeck and Copenhagen University and has a budget of 25.6 DKK mill. Please refer to press release in Danish.
Please refer to the press release (in Danish): http://hoejteknologifonden.dk/projektgalleri/19_december_2011_14_nye_investeringer/graeshopper_giver_nye_laegemidler/
We are proud to present Entomopharm’s newly established Scientific Advisory Board:
The Scientific Advisory Board for EntomoPharm consists of international researchers from academia, biotech and pharmaceutical industry. The objective of the scientific advisory board is to provide independent advice and peer review to EntomoPharm on the scientific, technical and commercial aspects of ADMET modeling in insects.
Members of the board:
Professor Joan Abbott, Dr. Pieter Gaillard, Dr. Gerhard Gross, Professor Margareta Hammarlund-Udenaes, Professor Steen Honoré
Click here to read more about the members of our Advisory Board and their impressive credentials.
Models for predicting blood-brain barrier permeation. Nielsen PA, Andersson O, Hansen SH, Simonsen KB, Andersson G (2011). Drug Discovery Today, June; 16(11-12):472-5
We hope that you will like the new look and feel of our website. Please come back and check for updates as we will be adding more content.
The Danish Growth Fund (Vaekstfonden) has invested series A venture capital into EntomoPharm to support our commercialization efforts.
